Clinical Trials Logo

Relapsed Acute Myeloid Leukemia clinical trials

View clinical trials related to Relapsed Acute Myeloid Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06177067 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Start date: April 21, 2024
Phase: Phase 1
Study type: Interventional

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective - To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives - Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).

NCT ID: NCT06017258 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Start date: August 22, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

NCT ID: NCT04891757 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Start date: June 14, 2021
Phase: Phase 1
Study type: Interventional

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.

NCT ID: NCT04582864 Recruiting - Clinical trials for Relapsed Acute Myeloid Leukemia

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Start date: May 20, 2021
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional therapeutic efficacy.